

Supplementary Materials for

In Vivo CRISPR Gene Editing in Patients with Herpes Stromal Keratitis

Anji Wei¹ †, Di Yin² †, Zimeng Zhai¹ †, Sikai Ling³, Huangying Le², Lijia Tian¹, Jianjiang Xu¹,
Soren R Paludan⁴, Yujia Cai^{2*}, Jiaxu Hong^{1, 5, 6*}.

†These authors contributed equally to this work.

*Corresponding author. Email: JH: Jiaxu.hong@fdeent.org, YC: yujia.cai@sjtu.edu.cn.

Other Supplementary Materials for this manuscript include the following:

Supplemental Movie

Table S1. Visual acuity, intraocular pressure and virus tests.

		1 day	7 days	1 month	2 months	3 months	6 months	12 months
		pre-injection	post-injection	post-injection	post-injection	post-injection	post-injection	post-injection
Patient 1	Best-corrected visual acuity	Light perception	Finger count	Finger count	Finger count	Finger count	20/100	20/100
	Intraocular pressure (mmHg)	Undetectable	12.0	10.4	16	15.3	8	21.3
	HSV-1 tests (Ct value)	21.35 (Cornea)	-	28.37(Tear swab)	-	-	-	-
		28.37 (Aqueous)	24.09(Tear swab)	31.49(Tear swab)	-	-	-	-
30.55*(Tear swab)		-	31.08(Tear swab)	-	-	-	-	
Patient 2	Best-corrected visual acuity	Hand motion	20/250	20/167	20/100	20/67	20/133	20/133
	Intraocular pressure (mmHg)	Undetectable	11.0	16.3	16.4	12.4	7.3	15.0
	HSV-1 tests (Ct value)	26.34 (Cornea)	-	-	-	-	-	-
		36.50 (Aqueous)	-	-	-	-	-	-
35.01*(Tear swab)		-	-	-	-	-	-	
Patient 3	Best-corrected visual acuity	Hand motion	Hand motion	Hand motion	Hand motion	Hand motion	Hand motion	Finger count
	Intraocular pressure (mmHg)	Undetectable	n.a.	15.0	24.1	18.5	18.1	19.3
	HSV-1 tests (Ct value)	34.9 (Cornea)	-	-	-	-	-	-
		- (Aqueous)	-	-	-	-	-	-
29.5 (Tear swab)		-	-	-	-	-	-	

*Mean HSV-1 titer (Ct value) of three simultaneously sampled tear swabs; n.a., not available; -, Ct value undetectable.

Table S2. Visual acuity, intraocular pressure and virus tests.

Patient	Adverse Event	Start Date	End Date	Placebo Related	Severity	Outcome	Treatment
1	corneal edema	11/2020	11/2020	possibly related	mild	resolved	concomitant medication
	conjunctival injection	11/2020	11/2020	unlikely to be related	mild	resolved	concomitant medication
	hyphema	11/2020	11/2020	unrelated	mild	resolved	none
	neurotrophic keratitis	5/2021	/	unrelated	mild	unresolved	concomitant medication
	uncontrolled corneal ulcer	9/2021	11/2021	unrelated	moderate	resolved	penetrating keratoplasty
	cataract	n.a.	11/2021	unrelated	mild	resolved	cataract surgery
	secondary glaucoma	10/2021	12/2021	unrelated	mild	resolved	concomitant medication
2	corneal edema	1/2021	1/2021	possibly related	mild	resolved	concomitant medication
	conjunctival injection	1/2021	1/2021	unlikely to be related	mild	resolved	concomitant medication
	itching	2/2021	3/2021	unrelated	mild	resolved	concomitant medication
	endophthalmitis	7/2021	7/2021	unrelated	moderate	resolved	vitrectomy and antibiotic injection
	cataract	n.a.	/	unrelated	mild	unresolved	none
3	corneal edema	5/2021	5/2021	possibly related	mild	resolved	concomitant medication
	conjunctival injection	5/2021	5/2021	unlikely to be related	mild	resolved	concomitant medication
	graft rejection	8/2021	10/2021	unrelated	mild	resolved	concomitant medication
	secondary glaucoma	7/2021	8/2021	unrelated	mild	resolved	concomitant medication
	cataract	n.a.	/	unrelated	mild	unresolved	none

A

			20		40		60	
HSV-1 KOS UL23	MASYPCHQHA	SAFDQAARSR	GHSNRRTALR	PRRQEQATEV	RLEQKMP TLL	RVYIDGPHGM	60	
HSV-1 17+ UL23	MASYPCHQHA	SAFDQAARSR	GH ^N NRRTALR	PRRQ ^K ATEV	RLEQKMP TLL	RVYIDGPHGM	60	
Patient 1 UL23	- - - YPCHQHA	SAFDQAARSR	GHSNRRTALR	PRRQEQATEV	RLEQKMP TLL	RVYIDGPHGM	57	
Patient 2 UL23	- - - YPCHQHA	SAFDQAARSR	GHSNRRTALR	PRRQEQATEV	RLEQKMP TLL	RVYIDGPHGM	57	
Patient 3 UL23	- - - YPCHQHA	SAFDQAARSR	GHSNRRTALR	PRRQEQATEV	RLEQKMP TLL	RVYIDGPHGM	57	
			80		100		120	
HSV-1 KOS UL23	GKTTTTQLLV	ALGSRDDIVY	VPEPMTYWQV	LGASETIANI	YTTQHRLDQG	EISAGDAAVV	120	
HSV-1 17+ UL23	GKTTTTQLLV	ALGSRDDIVY	VPEPMTY ^R WV	LGASETIANI	YTTQHRLDQG	EISAGDAAVV	120	
Patient 1 UL23	GKTTTTQLLV	ALGSRDDIVY	VPEPMTYWQV	LGASETIANI	YTTQHRLDQG	EISAGDAAVV	117	
Patient 2 UL23	GKTTTTQLLV	ALGSRDDIVY	VPEPMTYWQV	LGASETIANI	YTTQHRLDQG	EISAGDAAVV	117	
Patient 3 UL23	GKTTTTQLLV	ALGSRDDIVY	VPEPMTYWQV	LGASETIANI	YTTQHRLDQG	EISAGDAAVV	117	
			140		160		180	
HSV-1 KOS UL23	MTSAQITMGM	PYAVTDAVLA	PHIGGEAGSS	HAPPPALTLI	FDRHP IAALL	CYPAARYLMG	180	
HSV-1 17+ UL23	MTSAQITMGM	PYAVTDAVLA	PHIGGEAGSS	HAPPPALTLI	FDRHP IAALL	CYPAARYLMG	180	
Patient 1 UL23	MTSAQITMGM	PYAVTDAVLA	PHIGGEAGSS	HAPPPALTLI	FDRHP IAALL	CYPAARYLMG	177	
Patient 2 UL23	MTSAQITMGM	PYAVTDAVLA	PHIGGEAGSS	HAPPPALTLI	FDRHP IAALL	CYPAARYLMG	177	
Patient 3 UL23	MTSAQITMGM	PYAVTDAVLA	PHIGGEAGSS	HAPPPALTLI	FDRHP IAALL	CYPAARYLMG	177	
			200		220		240	
HSV-1 KOS UL23	SMT PQAVLAF	VALIPPTLPG	TNIVLGALPE	DRHIDRLAKR	QRPGERDLA	MLAAIRRVYG	240	
HSV-1 17+ UL23	SMT PQAVLAF	VALIPPTLPG	TNIVLGALPE	DRHIDRLAKR	QRPGERDLA	MLAAIRRVYG	240	
Patient 1 UL23	SMT PQAVLAF	VALIPPTLPG	TNIVLGALPE	DRHIDRLAKR	QRPGERDLA	MLAAIRRVYG	237	
Patient 2 UL23	SMT PQAVLAF	VALIPPTLPG	TNIVLGALPE	DRHIDRLAKR	QRPGERDLA	MLAAIRRVYG	237	
Patient 3 UL23	SMT PQAVLAF	VALIPPTLPG	TNIVLGALPE	DRHIDRLAKR	QRPGERDLA	MLAAIRRVYG	237	
			260		280		300	
HSV-1 KOS UL23	LLANTVRYLQ	GGGSWREDWG	QLSGTAVPPQ	GAEPQSNAGP	RPHIGDTLFT	LFRAPELLAP	300	
HSV-1 17+ UL23	LLANTVRYLQ	GGGSWREDWG	QLSG ^A AVPPQ	GAEPQSNAGP	RPHIGDTLFT	LFRAPELLAP	300	
Patient 1 UL23	LLANTVRYLQ	GGGSWREDWG	QLSGTAVPPQ	GAEPQSNAGP	RPHIGDTLFT	LFRAPELLAP	297	
Patient 2 UL23	LLANTVRYLQ	GGGSWREDWG	QLSGTAVPPQ	GAEPQSNAGP	RPHIGDTLFT	LFRAPELLAP	297	
Patient 3 UL23	LLANTVRYLQ	GGGSWREDWG	QLSGTAVPPQ	GAEPQSNAGP	RPHIGDTLFT	LFRAPELLAP	297	
			320		340		360	
HSV-1 KOS UL23	NGDLYNVFAW	ALDVLAKRLR	PMHVFILDYD	QSPAGCRDAL	LQLTSGMVQT	HVTTPGS IPT	360	
HSV-1 17+ UL23	NGDLYNVFAW	ALDVLAKRLR	PMHVFILDYD	QSPAGCRDAL	LQLTSGMVQT	HVTTPGS IPT	360	
Patient 1 UL23	NGDLYNVFAW	ALDVLAKRLR	PMHVFILDYD	QSPAGCRDAL	LQLTSGMVQT	HVTTPGS IPT	357	
Patient 2 UL23	NGDLYNVFAW	ALDVLAKRLR	PMHVFILDYD	QSPAGCRDAL	LQLTSGMVQT	HVTTPGS IPT	357	
Patient 3 UL23	NGDLYNVFAW	ALDVLAKRLR	PMHVFILDYD	QSPAGCRDAL	LQLTSGMVQT	HVTTPGS IPT	357	
HSV-1 KOS UL23	ICDLARTFAR	EMGEAN					377	
HSV-1 17+ UL23	ICDLARTFAR	EMGEAN					377	
Patient 1 UL23	ICDLARTFAR	EMGEAN					374	
Patient 2 UL23	ICDLARTFAR	EMGEAN					374	
Patient 3 UL23	ICDLARTFAR	EMGEAN					374	

B

			20		40		60
HSV-1 KOS UL30	MFSGGGGPLS	PGGKSAARAA	SGFFAPAGPR	GAGRGGPPPCL	RQNFYNPYLA	PVGTQQKPTG	60
HSV-1 17+ UL30	MFSGGGGPLS	PGGKSAARAA	SGFFAPAGPR	GASRGPPPCL	RQNFYNPYLA	PVGTQQKPTG	60
Patient 1 UL30	-----	-----RAA	SGFFAPAGPR	GASRGPPPCL	RQNFYNPYLA	PVGTQQKPTG	43
Patient 2 UL30	-----	-----RAA	SGFFAPAGPR	GAGRGGPPPCL	RQNFYNPYLA	PVGTQQKPTG	43
Patient 3 UL30	-----	-----RAA	SGFFAPAGPR	GAGRGGPPPCL	RQNFYNPYLA	PVGTQQKPTG	43
			80		100		120
HSV-1 KOS UL30	PTQRHTYYSE	CDEFRFIAPR	VLDEDAPPEK	RAGVHDGHLK	RAPKVYCGGD	ERDVLRVGSG	120
HSV-1 17+ UL30	PTQRHTYYSE	CDEFRFIAPR	VLDEDAPPEK	RAGVHDGHLK	RAPKVYCGGD	ERDVLRVGSG	120
Patient 1 UL30	PTQRHTYYSE	CDEFRFIAPR	VLDEDAPPEK	RAGVHDGHLK	RAPKVYCGGD	ERDVLRVGSG	103
Patient 2 UL30	PTQRHTYYSE	CDEFRFIAPR	VLDEDAPPEK	RAGVHDGHLK	RAPKVYCGGD	ERDVLRVGSG	103
Patient 3 UL30	PTQRHTYYSE	CDEFRFIAPR	VLDEDAPPEK	RAGVHDGHLK	RAPKVYCGGD	ERDVLRVGSG	103
			140		160		180
HSV-1 KOS UL30	GFWPRRSRLW	GGVDHAPAGF	NPTVTVFHVV	DILENVEHAY	GMRAAQFHAR	FMDAITPTGT	180
HSV-1 17+ UL30	GFWPRRSRLW	GGVDHAPAGF	NPTVTVFHVV	DILENVEHAY	GMRAAQFHAR	FMDAITPTGT	180
Patient 1 UL30	GFWPRRSRLW	GGVDHAPAGF	NPTVTVFHVV	DILENVEHAY	GMRAAQFHAR	FMDAITPTGT	163
Patient 2 UL30	GFWPRRSRLW	GGVDHAPAGF	NPTVTVFHVV	DILENVEHAY	GMRAAQFHAR	FMDAITPTGT	163
Patient 3 UL30	GFWPRRSRLW	GGVDHAPAGF	NPTVTVFHVV	DILENVEHAY	GMRAAQFHAR	FMDAITPTGT	163
			200		220		240
HSV-1 KOS UL30	VITLLGLTPE	GHRVAVHVVY	TRQFYFNMKE	EVDRLQCRA	PRDLCERMAA	ALRESPGASF	240
HSV-1 17+ UL30	VITLLGLTPE	GHRVAVHVVY	TRQFYFNMKE	EVDRLQCRA	PRDLCERMAA	ALRESPGASF	240
Patient 1 UL30	VITLLGLTPE	GHRVAVHVVY	TRQFYFNMKE	EVDRLQCRA	PRDLCERMAA	ALRESPGASF	223
Patient 2 UL30	VITLLGLTPE	GHRVAVHVVY	TRQFYFNMKE	EVDRLQCRA	PRDLCERMAA	ALRESPGASF	223
Patient 3 UL30	VITLLGLTPE	GHRVAVHVVY	TRQFYFNMKE	EVDRLQCRA	PRDLCERMAA	ALRESPGASF	223
			260		280		300
HSV-1 KOS UL30	RGISADHFEA	EVVERTDVYY	YETRPALFYR	VYVRSGRVLS	YLCDNFCPAI	KKYEGGV DAT	300
HSV-1 17+ UL30	RGISADHFEA	EVVERTDVYY	YETRPALFYR	VYVRSGRVLS	YLCDNFCPAI	KKYEGGV DAT	300
Patient 1 UL30	RGISADHFEA	EVVERTDVYY	YETRPALFYR	VYVRSGRVLS	YLCDNFCPAI	KKYEGGV DAT	283
Patient 2 UL30	RGISADHFEA	EVVERTDVYY	YETRPALFYR	VYVRSGRVLS	YLCDNFCPAI	KKYEGGV DAT	283
Patient 3 UL30	RGISADHFEA	EVVERTDVYY	YETRPALFYR	VYVRSGRVLS	YLCDNFCPAI	KKYEGGV DAT	283
			320		340		360
HSV-1 KOS UL30	TRFILDNPGF	VTFGWYRLKP	GRNNTLAQPR	APMAFGTSSD	VEFNCTADNL	AIEGGMSDLP	360
HSV-1 17+ UL30	TRFILDNPGF	VTFGWYRLKP	GRNNTLAQPR	APMAFGTSSD	VEFNCTADNL	AIEGGMSDLP	360
Patient 1 UL30	TRFILDNPGF	VTFGWYRLKP	GRNNTLAQPR	APMAFGTSSD	VEFNCTADNL	AIEGGMSDLP	343
Patient 2 UL30	TRFILDNPGF	VTFGWYRLKP	GRNNTLAQPR	APMAFGTSSD	VEFNCTADNL	AIEGGMSDLP	343
Patient 3 UL30	TRFILDNPGF	VTFGWYRLKP	GRNNTLAQPR	APMAFGTSSD	VEFNCTADNL	AIEGGMSDLP	343
			380		400		420
HSV-1 KOS UL30	AYKLMCFDIE	CKAGGEDELA	FPVAGHPEDL	VIQISCLLYD	LSTTALEHVL	LFSLGSCDLP	420
HSV-1 17+ UL30	AYKLMCFDIE	CKAGGEDELA	FPVAGHPEDL	VIQISCLLYD	LSTTALEHVL	LFSLGSCDLP	420
Patient 1 UL30	AYKLMCFDIE	CKAGGEDELA	FPVAGHPEDL	VIQISCLLYD	LSTTALEHVL	LFSLGSCDLP	403
Patient 2 UL30	AYKLMCFDIE	CKAGGEDELA	FPVAGHPEDL	VIQISCLLYD	LSTTALEHVL	LFSLGSCDLP	403
Patient 3 UL30	AYKLMCFDIE	CKAGGEDELA	FPVAGHPEDL	VIQISCLLYD	LSTTALEHVL	LFSLGSCDLP	403
			440		460		480
HSV-1 KOS UL30	ESHNELAAR	GLPTPVVLEF	DSEFEMLLAF	MTLVKQYGPE	FVTGYN I INF	DWPFLAKLT	480
HSV-1 17+ UL30	ESHNELAAR	GLPTPVVLEF	DSEFEMLLAF	MTLVKQYGPE	FVTGYN I INF	DWPFLAKLT	480
Patient 1 UL30	ESHNELAAR	GLPTPVVLEF	DSEFEMLLAF	MTLVKQYGPE	FVTGYN I INF	DWPFLAKLT	463
Patient 2 UL30	ESHNELAAR	GLPTPVVLEF	DSEFEMLLAF	MTLVKQYGPE	FVTGYN I INF	DWPFLAKLT	463
Patient 3 UL30	ESHNELAAR	GLPTPVVLEF	DSEFEMLLAF	MTLVKQYGPE	FVTGYN I INF	DWPFLAKLT	463
			500		520		540
HSV-1 KOS UL30	DIYKVPLDGY	GRMNGRGVFR	VWDIGQSHFQ	KRSKIKVNGM	VNIDMYGIIT	DKIKLSSYKL	540
HSV-1 17+ UL30	DIYKVPLDGY	GRMNGRGVFR	VWDIGQSHFQ	KRSKIKVNGM	VNIDMYGIIT	DKIKLSSYKL	540
Patient 1 UL30	DIYKVPLDGY	GRMNGRGVFR	VWDIGQSHFQ	KRSKIKVNGM	VNIDMYGIIT	DKIKLSSYKL	523
Patient 2 UL30	DIYKVPLDGY	GRMNGRGVFR	VWDIGQSHFQ	KRSKIKVNGM	VNIDMYGIIT	DKIKLSSYKL	523
Patient 3 UL30	DIYKVPLDGY	GRMNGRGVFR	VWDIGQSHFQ	KRSKIKVNGM	VNIDMYGIIT	DKIKLSSYKL	523
			560		580		600
HSV-1 KOS UL30	NAVAEAVLKD	KKKDLSYRDI	PAYYATGPAQ	RGVIGEYCIQ	DSLLVGQLFF	KFLPHLELSA	600
HSV-1 17+ UL30	NAVAEAVLKD	KKKDLSYRDI	PAYYAAGPAQ	RGVIGEYCIQ	DSLLVGQLFF	KFLPHLELSA	600
Patient 1 UL30	NAVAEAVLKD	KKKDLSYRDI	PAYYAAGPAQ	RGVIGEYCIQ	DSLLVGQLFF	KFLPHLELSA	583
Patient 2 UL30	NAVAEAVLKD	KKKDLSYRDI	PAYYATGPAQ	RGVIGEYCIQ	DSLLVGQLFF	KFLPHLELSA	583
Patient 3 UL30	NAVAEAVLKD	KKKDLSYRDI	PAYYATGPAQ	RGVIGEYCIQ	DSLLVGQLFF	KFLPHLELSA	583
			620		640		660
HSV-1 KOS UL30	VARLAGINIT	RTIYDQQQIR	VFTCLLRLAD	QKGFILPDTQ	GRFRGAGGEE	PKRPAAAARE	660
HSV-1 17+ UL30	VARLAGINIT	RTIYDQQQIR	VFTCLLRLAD	QKGFILPDTQ	GRFRGAGGEE	PKRPAAAARE	660
Patient 1 UL30	VARLAGINIT	RTIYDQQQIR	VFTCLLRLAD	QKGFILPDTQ	GRFRGAGGEE	PKRPAAAARE	643
Patient 2 UL30	VARLAGINIT	RTIYDQQQIR	VFTCLLRLAD	QKGFILPDTQ	GRFRGAGGEE	PKRPAAAARE	643
Patient 3 UL30	VARLAGINIT	RTIYDQQQIR	VFTCLLRLAD	QKGFILPDTQ	GRFRGAGGEE	PKRPAAAARE	643
			680		700		720
HSV-1 KOS UL30	EERPEEEGED	EDEREEGGGE	REPEGARETA	GRHVGYQGAR	VLDPTSGFHV	NPVVVDFAS	720
HSV-1 17+ UL30	EERPEEEGED	EDEREEGGGE	REPEGARETA	GRHVGYQGAR	VLDPTSGFHV	NPVVVDFAS	720
Patient 1 UL30	EERPEEEGED	EDEREEGGGE	REPEGARETA	GRHVGYQGAR	VLDPTSGFHV	NPVVVDFAS	703
Patient 2 UL30	EERPEEEGED	EDEREEGGGE	REPEGARETA	GRHVGYQGAR	VLDPTSGFHV	NPVVVDFAS	703
Patient 3 UL30	EERPEEEGED	EDEREEGGGE	REPEGARETA	GRHVGYQGAR	VLDPTSGFHV	NPVVVDFAS	703

			740			760		780	
HSV-1 KOS UL30	LYPSI IQAHN	LCFSTLSLRA	DAVAHLEAGK	DYLEIEVGGR	RLFFVKAHVR	ESLLSILLRD		780	
HSV-1 17+ UL30	LYPSI IQAHN	LCFSTLSLRA	DAVAHLEAGK	DYLEIEVGGR	RLFFVKAHVR	ESLLSILLRD		780	
Patient 1 UL30	LYPSI IQAHN	LCFSTLSLRA	DAVAHLEAGK	DYLEIEVGGR	RLFFVKAHVR	ESLLSILLRD		763	
Patient 2 UL30	LYPSI IQAHN	LCFSTLSLRA	DAVAHLEAGK	DYLEIEVGGR	RLFFVKAHVR	ESLLSILLRD		763	
Patient 3 UL30	LYPSI IQAHN	LCFSTLSLRA	DAVAHLEAGK	DYLEIEVGGR	RLFFVKAHVR	ESLLSILLRD		763	
			800			820		840	
HSV-1 KOS UL30	WLAMRKQIRS	RIPQSSPEEA	VLLDKQQAAI	KVVCNSVYGF	TGVQHGLLPC	LHVAATVTTI		840	
HSV-1 17+ UL30	WLAMRKQIRS	RIPQSSPEEA	VLLDKQQAAI	KVVCNSVYGF	TGVQHGLLPC	LHVAATVTTI		840	
Patient 1 UL30	WLAMRKQIRS	RIPQSSPEEA	VLLDKQQAAI	KVVCNSVYGF	TGVQHGLLPC	LHVAATVTTI		823	
Patient 2 UL30	WLAMRKQIRS	RIPQSSPEEA	VLLDKQQAAI	KVVCNSVYGF	TGVQHGLLPC	LHVAATVTTI		823	
Patient 3 UL30	WLAMRKQIRS	RIPQSSPEEA	VLLDKQQAAI	KVVCNSVYGF	TGVQHGLLPC	LHVAATVTTI		823	
			860			880		900	
HSV-1 KOS UL30	GREMLLATRE	YVHARWAAFE	QLLADFPEAA	DMRAPGPYSM	RIIYGDTSI	FVLCRGLTAA		900	
HSV-1 17+ UL30	GREMLLATRE	YVHARWAAFE	QLLADFPEAA	DMRAPGPYSM	RIIYGDTSI	FVLCRGLTAA		900	
Patient 1 UL30	GREMLLATRE	YVHARWAAFE	QLLADFPEAA	DMRAPGPYSM	RIIYGDTSI	FVLCRGLTAA		883	
Patient 2 UL30	GREMLLATRE	YVHARWAAFE	QLLADFPEAA	DMRAPGPYSM	RIIYGDTSI	FVLCRGLTAA		883	
Patient 3 UL30	GREMLLATRE	YVHARWAAFE	QLLADFPEAA	DMRAPGPYSM	RIIYGDTSI	FVLCRGLTAA		883	
			920			940		960	
HSV-1 KOS UL30	GLTAMGDKMA	SHISRALFLP	PIKLECEKTF	TKLLLIAKKK	YIGVIYGGKM	LIKGVDLVRK		960	
HSV-1 17+ UL30	GLTAMGDKMA	SHISRALFLP	PIKLECEKTF	TKLLLIAKKK	YIGVIYGGKM	LIKGVDLVRK		960	
Patient 1 UL30	GLTAMGDKMA	SHISRALFLP	PIKLECEKTF	TKLLLIAKKK	YIGVIYGGKM	LIKGVDLVRK		943	
Patient 2 UL30	GLTAMGDKMA	SHISRALFLP	PIKLECEKTF	TKLLLIAKKK	YIGVIYGGKM	LIKGVDLVRK		943	
Patient 3 UL30	GLTAMGDKMA	SHISRALFLP	PIKLECEKTF	TKLLLIAKKK	YIGVIYGGKM	LIKGVDLVRK		943	
			980			1,000		1,020	
HSV-1 KOS UL30	NNCAF INRTS	RALVDLLFYD	DTVSGAAAAL	AERPAEEWLA	RPLPEGLQAF	GAVLVDAHRR		1020	
HSV-1 17+ UL30	NNCAF INRTS	RALVDLLFYD	DTVSGAAAAL	AERPAEEWLA	RPLPEGLQAF	GAVLVDAHRR		1020	
Patient 1 UL30	NNCAF INRTS	RALVDLLFYD	DTVSGAAAAL	AERPAEEWLA	RPLPEGLQAF	GAVLVDAHRR		1003	
Patient 2 UL30	NNCAF INRTS	RALVDLLFYD	DTVSGAAAAL	AERPAEEWLA	RPLPEGLQAF	GAVLVDAHRR		1003	
Patient 3 UL30	NNCAF INRTS	RALVDLLFYD	DTVSGAAAAL	AERPAEEWLA	RPLPEGLQAF	GAVLVDAHRR		1003	
			1,040			1,060		1,080	
HSV-1 KOS UL30	ITDPERDIQD	FVLTAELSRH	PRAYTNKRLA	HLTVYYKLMA	RRAQVPSIKD	RIPYVIVAQT		1080	
HSV-1 17+ UL30	ITDPERDIQD	FVLTAELSRH	PRAYTNKRLA	HLTVYYKLMA	RRAQVPSIKD	RIPYVIVAQT		1080	
Patient 1 UL30	ITDPERDIQD	FVLTAELSRH	PRAYTNKRLA	HLTVYYKLMA	RRAQVPSIKD	RIPYVIVAQT		1063	
Patient 2 UL30	ITDPERDIQD	FVLTAELSRH	PRAYTNKRLA	HLTVYYKLMA	RRAQVPSIKD	RIPYVIVAQT		1063	
Patient 3 UL30	ITDPERDIQD	FVLTAELSRH	PRAYTNKRLA	HLTVYYKLMA	RRAQVPSIKD	RIPYVIVAQT		1063	
			1,100			1,120		1,140	
HSV-1 KOS UL30	REVEETVARL	AALRELDAAA	PGDEPAPPAA	LPSPAKRPRE	TPSHADPPGG	ASKPRKLLVS		1140	
HSV-1 17+ UL30	REVEETVARL	AALRELDAAA	PGDEPAPPAA	LPSPAKRPRE	TPSPADPPGG	ASKPRKLLVS		1140	
Patient 1 UL30	REVEETVARL	AALRELDAAA	PGDEPAPPAA	LPSPAKRPRE	TPSPADPPGG	ASKPRKLLVS		1123	
Patient 2 UL30	REVEETVARL	AALRELDAAA	PGDEPAPPAA	LPSPAKRPRE	TPSHADPPGG	ASKPRKLLVS		1123	
Patient 3 UL30	REVEETVARL	AALRELDAAA	PGDEPAPPAA	LPSPAKRPRE	TPSHADPPGG	ASKPRKLLVS		1123	
			1,160			1,180		1,200	
HSV-1 KOS UL30	ELAEDPAYAI	AHGVALNTDY	YFSHLLGAAC	VTFKALFGNN	AKITESLLKR	FIPVWHPPD		1200	
HSV-1 17+ UL30	ELAEDPAYAI	AHGVALNTDY	YFSHLLGAAC	VTFKALFGNN	AKITESLLKR	FIPVWHPPD		1200	
Patient 1 UL30	ELAEDPAYAI	AHGVALNTDY	YFSHL-----	-----	-----	-----		1152	
Patient 2 UL30	ELAEDPAYAI	AHGVALNTDY	YFSHL-----	-----	-----	-----		1152	
Patient 3 UL30	ELAEDPAYAI	AHGVALNTDY	YFSHL-----	-----	-----	-----		1152	
			1,220						
HSV-1 KOS UL30	DVAARLRAAG	FGAVGAGATA	EETRMLHRA	FDTLA				1235	
HSV-1 17+ UL30	DVAARLRTAG	FGAVGAGATA	EETRMLHRA	FDTLA				1235	
Patient 1 UL30				1152	
Patient 2 UL30				1152	
Patient 3 UL30				1152	

Fig. S1. Amino acids alignment for TK and DNA pol. HSV-1 strains were isolated from the three participants and sequenced for genes encoding thymidine kinase (TK, UL23) and DNA polymerase (DNA pol, UL30). Letter in red color indicated changed amino acids in TK (**A**) and DNA pol (**B**). HSV-1 KOS and 17syn+ strains were used as references. Only amino-acid changes different from both KOS and 17syn+ simultaneously are considered as ACV resistant mutations.




Fig. S2. Postoperative B-scan ultrasonography of patient 3. B-scan ultrasonography of the patient 3 on 7 days (A), 1 month (B), 3 months (C) and 6 months (D) post-injection. Continuous ribbon-like echo was found in the posterior vitreous body, indicating vitreous opacity with posterior detachment.




Fig. S3. Postoperative B-scan ultrasonography of patient 2. B-scan ultrasonography results of patient 2 on 6 months (A) and 9 months (B) post-injection showed no remarkable changes in the vitreous body.




Fig. S4. Postoperative B-scan ultrasonography of patient 1. B-scan ultrasonography of patient 1 on 7 days (A), 1 month (B), 6 months (C) and 12 months (D) post-injection revealed no remarkable changes in the vitreous body.




Fig. S5. Spectral-domain OCT of the retina of patient 2. The spectral-domain OCT of patient 2's retina was performed at 6 months post-injection using Cirrus OCT 5000 (Zeiss). The structure of his fundus showed no obvious exception after the administration of HELP.

Scan Angle: 0°

Spacing: 0.25 mm

Length: 6 mm





Fig. S6. Spectral-domain OCT of the retina of patient 1. The optical coherence tomography revealed mild center-involved intraretinal fluid and subfoveal fluid in the right eye of patient 1 at six months after the treatment. The ellipsoid zone was intact. We continue to follow up on this situation without any intervention.

5


A

Diagnosis:
1_Pattern-VEP 2.0&1.0 deg (Monitor)




Normals	-	96-109	-	7.08µV-17.7µV	
Channel	N75 [ms]	P100 [ms]	N135 [ms]	N75-P100	P100-N135
1 R1 2,0 deg	70.5	102.2	150.3	8.13µV	13.3µV
2 R1 1,0 deg	76.3	104.5	150.3	3.94µV (!)	11.7µV
3 L1 2,0 deg	62.8	108.0	130.3	6.51µV (!)	4.14µV
4 L1 1,0 deg	70.5	118.0 (!)	125.6	83.5nV (!)	2.01µV

2_Pattern-VEP 30 min&15 min (Monitor)



Normals	-	105-126	-	7.00µV-42.5µV	
Channel	N75 [ms]	P100 [ms]	N135 [ms]	N75-P100	P100-N135
1 R1 30 min	89.8	118.0	150.3	7.13µV	7.29µV
2 R1 15 min					
3 L1 30 min	78.1	114.5	139.1	5.40µV (!)	4.80µV
4 L1 15 min					


B



PVEP: 图形翻转.60'					
No.	N75 [ms]	P100 [ms]	N135 [ms]	N75-P100 [μ V]	P100-N135 [μ V]
1R	66.0	106.0	149.5	4.9	3.4
2L	83.5	130.0	183.5	4.8	5.8
PVEP: 图形翻转.30'					
No.	N75 [ms]	P100 [ms]	N135 [ms]	N75-P100 [μ V]	P100-N135 [μ V]
1R	75.5	112.0	182.0	6.3	6.0
2L	90.5	130.0	176.0	2.8	3.1
PVEP: 图形翻转.15'					
No.	N75 [ms]	P100 [ms]	N135 [ms]	N75-P100 [μ V]	P100-N135 [μ V]
1R	80.0	109.0	161.5	3.2	1.9
2L	87.0	130.0	170.0	3.0	4.9

Fig. S7. Retina ERG of patient 3. The light-stimulated electrical activity of the retina indicates no remarkable change in terms of retinal function in patient 3 (A: pre-injection; B: six months post-injection).

5



PVEP: 图形翻转.60'

No.	N75 [ms]	P100 [ms]	N135 [ms]	N75-P100 [µV]	P100-N135 [µV]
1R	70.0	118.5	144.5	7.9	4.2
2L	67.0	110.0	135.0	14.6	11.8



PVEP: 图形翻转.30'

No.	N75 [ms]	P100 [ms]	N135 [ms]	N75-P100 [µV]	P100-N135 [µV]
1R	55.0	103.5	126.5	4.7	-0.6
2L	76.0	104.0	138.0	9.8	6.4

PVEP: 图形翻转.15'

No.	N75 [ms]	P100 [ms]	N135 [ms]	N75-P100 [µV]	P100-N135 [µV]
1R	84.0	112.0	131.5	3.9	4.1
2L	86.0	110.0	138.0	10.5	1.2

Fig. S8. Retina ERG of patient 2. The light-stimulated electrical activity of retina indicates no significant change in terms of retinal function in patient 2 twelve months after the treatment.






Fig. S9. Retinal ERG examination of patient 1. ERG detected no obvious changes of rod or cone responses to light stimulus in patient 1. (A: pre-injection; B: twelve months post-injection)


Table S3. Intraocular bacterial and fungal culture results of patient 2. Gram+ cocci were found in the right eye of patient 2 during the vitrectomy 6 months after PK.

Culture	Presence	Species
Bacteria	+	Gram-positive cocci
Fungus	-	-

Patient 1


A

HR: 67 bpm QRS duration: 0.09s
P-R interval: 0.16s Q-T interval: 0.42s
QTc: 0.44 Axis: 66 °
V1R+V5S: 0.71mV V5R+V1S: 2.01mV




B

HR: 63 bpm QRS duration: 0.08s
P-R interval: 0.17s Q-T interval: 0.41s
QTc: 0.42 Axis: 61 °
V1R+V5S: 0.65mV V5R+V1S: 2.51mV



5

Fig. S10. The ECG examination. The pre- and postoperative ECG of patient 1 was unremarkable. (A: pre-injection; B: twelve months post-injection)






Fig. S11. Chest X-ray examination. The Chest X-ray of patient 1 showed no remarkable changes before (A) and twelve months (B) after the injection.

Table S4. Blood tests. The blood tests of patient 1 showed slight anemia, hypoproteinemia, and diabetes before the injection. We observed no abnormal changes which were related to the injection in these blood tests at 12-month follow-up.

Code	Pre-Injection	Twelve Months Post-Injection	Normal Range	Unit
White blood cell count	5.24	4.39	4.0~10.0	10 ⁹ /L
Red blood cell count	2.71 ↓	3.47 ↓	4.3~5.8	10 ¹² /L
Hemoglobin	106 ↓	122 ↓	130~175	g/l
Packed red blood cell volume	30.7 ↓	36.9 ↓	40~50	%
Red blood cell volume distribution width-coefficient of variation	15.1 ↑	15.2 ↑	10.0~15.0	%
Red blood cell volume distribution width-standard deviation	62.3 ↑	59.8 ↑	35.0~50.0	fL
Mean corpuscular volume	113.3 ↑	106.3 ↑	80.0~100.0	fL
Mean corpuscular hemoglobin	39.1 ↑	35.2 ↑	27.0~33.0	Pg
Mean corpuscular hemoglobin concentration	345	331	320~360	g/l
Platelet count	175	213	100~400	10 ⁹ /L
Platelet distribution width	9.7	11.1	9.0~17.00	
Thrombocytocrit	0.17	0.22	0.16~0.22	%
Mean platelet volume	9.7	10.2	9.0~16.0	fL
Platelet-larger cell ratio	21.6	25.0	14.0~46.0	%
Percentage of neutrophil	61.6	56.2	50.0~70.0	%
Percentage of lymphocyte	32.1	30.8	20.0~40.0	%
Percentage of eosinophil	1.5	3.0	0.5~5.0	%
Percentage of monocyte	4.4	8.9 ↑	3.0~8.0	%
Percentage of basophil	0.4	1.1 ↑	0.0~1.0	%
Neutrophil count	3.23	2.47	2.0~7.0	10 ⁹ /L
Lymphocyte count	1.68	1.35	0.8~4.0	10 ⁹ /L
Monocyte count	0.23	0.39	0.10~0.80	10 ⁹ /L
Eosinophil count	0.08	0.13	0.00~0.50	10 ⁹ /L
Basophil count	0.02	0.05	0.00~0.10	10 ⁹ /L
Code	Pre-Injection	Twelve Months Post-Injection	Normal Range	Unit
Alanine aminotransferase	22	31	0~65	u/l
Aspartate aminotransferase	25	30	15~37	u/l
Total protein	67	71	64~82	g/l

Albumin	47		43		35~54	g/l
Globulin	20		28		20~40	g/l
Albumin/globulin	2.4		1.5		1.2~2.5	
γ-Glutamyltransferase	55		37		15~85	u/l
Prealbumin	150	↓	200		200~400	mg/l
Alkaline phosphatase	134		137	↑	50~136	u/l
Blood urea nitrogen	6.8	↑	9.2	↑	2.5~6.4	mmol/l
Creatinine	78		90		53~115	umol/l
Uric acid	0.42	↑	0.38	↑	0.202~0.417	mmol/l
Total bilirubin	10		6		0~17	umol/l
Connect bilirubin	5		2		1~5	umol/l
Total bile acid	14.5	↑	14.4	↑	0.0~10.0	umol/l
High density lipoprotein	1.73		1.86		0.910~2.060	mmol/l
Low density lipoprotein	1.33		2.21		0.00~3.36	mmol/l
Apoprotein A	1.53		1.28		1.100~1.700	g/l
Apoprotein B	0.56	↓	0.76	↓	0.800~1.550	g/l
Apoprotein E	35		38		27~45	mg/l
Lipoprotein small a	25		42		0~300	mg/l
Small dense low density lipoprotein	0.74		1.20		0.26~1.36	mmol/l
Calcium	2.21		2.21		2.04~2.74	mmol/l
Phosphorus	1.24		1.15		0.80~1.60	mmol/l
Potassium	4.6		4.8		3.5~5.4	mmol/l
Sodium	145		143		135~147	mmol/l
Chloride	109	↑	103		96~108	mmol/l
Carbon dioxide binding capacity	22		24		21~32	mmol/l
Lactate dehydrogenase	172		153		81~234	u/l
Creatine kinase	75		95		39~308	u/l
Complement 3c	0.73	↓	0.71	↓	0.9~1.8	g/l
Complement 4	0.20		0.16		0.1~0.4	g/l
Complement 1q	108.7	↓	117.7	↓	159~233	mg/l
Total complement	68.7	↑	62.7	↑	32.5~58.3	u/ml
Haptoglobin	56.50		92.00		32~205	mg/dl
Blood glucose	6.1		6.9	↑	3.9~6.1	mmol/l
Total cholesterol	3.04		4.54		2.80~5.20	mmol/l
Triacylglycerol	0.77		0.70		0.34~2.26	mmol/l

Code	Pre-Injection		Twelve Months Post-Injection		Normal Range	Unit
Prothrombin time	13.7		12.7		11.0~14.5	sec
International normalized ratio	1.03		0.98		0.80~1.20	INR
Activated partial thromboplastin time	35.9		32.6		28~45	s
Thrombin time	16.3		17.2		14.0~21.0	s
Fibrinogen	2.70		3.01		2.00~4.00	g/l
D-Dimer	0.67	↑	0.75	↑	0.00~0.50	ug/ml
Prothrombin time ratio	95		105		70~150	%

Code	Pre-Injection		Twelve Months Post-Injection		Normal Range	Unit
Glycated hemoglobin	6.2	↑	6.2	↑	4.0~6.0	%

*Red font denotes an elevated clinical index than the normal range; pink font denotes a decreased clinical index than the normal range. Similarly hereinafter.

Table S5. Urine tests. The pre-injection and twelve months post-injection routine urinalysis of patient 1 was unremarkable.

Code	Pre-Injection	Twelve Months Post-Injection	Normal Range	Unit
Urine glucose	-	-	-	
Ketone body	-	-	-	
Occult blood	-	-	-	
Protein	-	-	-	
Nitrite	-	-	-	
Bilirubin	-	-	-	
Specific gravity	>=1.030 ↑	1.020	1.003~1.030	
Urine PH value	6.0	6.0	5.0~6.5	
Urobilinogen	16	16	3.0~16.0	umol/l
Leukocyte	-	-	-	
White blood cell count	2	2	0~28	/ul
Red blood cell count	1	6	0~17	/ul
Squamous epithelial cells	-	2	0~28	/ul
Non-squamous epithelial cells	-	1	0~6	/ul
Trichomonas	-	-	0~1	/ul
Kidney epithelial cells	-	-	0~6	/ul
Transparent tube	-	-	0~2	/ul
Particle tube	-	-	0~1	/LPF
Cell tube	-	-	0~1	/LPF
Triphosphate crystal	-	-		
Calcium oxalate crystal	-	-		
Leucine crystal	-	-		
Cystine crystals	-	-		

Table S6. Infectious diseases tests. The four transfusion-associated contagion tests (hepatitis B, hepatitis C, syphilis, AIDS) of patient 1 were unremarkable.

Code	Pre-Injection	Twelve Months Post-Injection
Hepatitis B virus surface antigen	Negative	Negative
Hepatitis B virus surface antibody	Negative	Negative
Hepatitis B virus e antigen	Negative	Negative
Hepatitis B virus e antibody	Negative	Negative
Hepatitis B virus core antibody	Negative	Negative
Hepatitis B virus antibody-immunoglobulin M	Negative	Negative
Hepatitis B virus pre-S1 antigen	Negative	Negative
Hepatitis C virus antibody	Negative	Negative
Treponema pallidum particle agglutination test	Negative	Negative
Rapid plasma regain test	Negative	Negative
Human immunodeficiency virus antibody	Negative	Negative

Patient 2

HR: 70 bp QRS duration: 0.08s
P-R interval: 0.17s Q-T interval: 0.35s
QTc: 0.38 Axis: 21 °
V1R+V5S: 0.67mV V5R+V1S: 2.88mV




Fig. S12. The ECG. The ECG of patient 2 showed counterclockwise transposition, indicating a possibly hypertrophic in the left ventricle. Slightly hypertrophy of the ventricle is not reckoned as a contraindication for corneal transplant surgery.

5



Fig. S13. Chest X-ray film. The chest X-ray result of patient 2 was unremarkable.

Table S7. Blood tests. The blood tests of patient 2 indicated mild hyperlipidemia, which had no obvious influence on the implementation of the surgery. We observed no notable changes related to the injection in these blood tests at 12-month follow-up.

Code	Pre-Injection	Twelve Months Post-Injection	Normal Range	Unit
White blood cell count	7.17	10.16 ↑	4.0~10.0	10 ⁹ /L
Red blood cell count	4.73	4.69	4.3~5.8	10 ¹² /L
Hemoglobin	148	144	130~175	g/l
Packed red blood cell volume	44.0	43.1	40~50	%
Red blood cell volume distribution width-coefficient of variation	12.1	12.9	10.0~15.0	%
Red blood cell volume distribution width-standard deviation	41.6	43.1	35.0~50.0	fL
Mean corpuscular volume	93.0	91.9	80.0~100.0	fL
Mean corpuscular hemoglobin	31.3	30.7	27.0~33.0	Pg
Mean corpuscular hemoglobin concentration	336	334	320~360	g/l
Platelet count	229	236	100~400	10 ⁹ /L
Platelet distribution width	9.3	9.8	9.0~17.00	
Thrombocytocrit	0.21	0.22	0.16~0.22	%
Mean platelet volume	9.1	9.2	9.0~16.0	fL
Platelet-larger cell ratio	17.7	18.4	14.0~46.0	%
Percentage of neutrophil	64.3	77.8 ↑	50.0~70.0	%
Percentage of lymphocyte	28.7	18.3 ↓	20.0~40.0	%
Percentage of eosinophil	1.0	0.3 ↓	0.5~5.0	%
Percentage of monocyte	5.6	3.1	3.0~8.0	%
Percentage of basophil	0.4	0.5	0.0~1.0	%
Neutrophil count	4.61	7.9 ↑	2.0~7.0	10 ⁹ /L
Lymphocyte count	2.06	1.86	0.8~4.0	10 ⁹ /L
Monocyte count	0.40	0.32	0.10~0.80	10 ⁹ /L
Eosinophil count	0.07	0.03	0.00~0.50	10 ⁹ /L
Basophil count	0.03	0.05	0.00~0.10	10 ⁹ /L
Code	Pre-Injection	Twelve Months Post-Injection	Normal Range	Unit
Alanine aminotransferase	17	19	0~65	u/l
Aspartate aminotransferase	17	15	15~37	u/l
Total protein	70	68	64~82	g/l

Albumin	46		42		35~54	g/l
Globulin	24		26		20~40	g/l
Albumin/globulin	1.9		1.6		1.2~2.5	
γ-Glutamyltransferase	33		37		15~85	u/l
Prealbumin	320		350		200~400	mg/l
Alkaline phosphatase	71		80		50~136	u/l
Blood urea nitrogen	5.5		7.5	↑	2.5~6.4	mmol/l
Creatinine	69		62		53~115	umol/l
Uric acid	0.25		0.32		0.202~0.417	mmol/l
Total bilirubin	16		10		0~17	umol/l
Connect bilirubin	5		2		1~5	umol/l
Total bile acid	2.5		11.2	↑	0.0~10.0	umol/l
High density lipoprotein	1.24		1.61		0.910~2.060	mmol/l
Low density lipoprotein	4.36	↑	4.72	↑	0.00~3.36	mmol/l
Apoprotein A	1.46		1.24		1.100~1.700	g/l
Apoprotein B	1.51		1.55		0.800~1.550	g/l
Apoprotein E	52	↑	46	↑	27~45	mg/l
Lipoprotein small a	41		47		0~75	nmol/l
Small dense low density lipoprotein	3.11	↑	2.70	↑	0.26~1.36	mmol/l
Calcium	2.34		2.25		2.04~2.74	mmol/l
Phosphorus	1.18		0.99		0.80~1.60	mmol/l
Potassium	4.2		4.0		3.5~5.4	mmol/l
Sodium	140		142		135~147	mmol/l
Chloride	104		101		96~108	mmol/l
Carbon dioxide binding capacity	23		21		21~32	mmol/l
Lactate dehydrogenase	168		182		81~234	u/l
Creatine kinase	122		128		39~308	u/l
Complement 3c	1.03		1.04		0.9~1.8	g/l
Complement 4	0.20		0.32		0.1~0.4	g/l
Complement 1q	154.5	↓	169.4		159~233	mg/l
Total complement	67.9	↑	63.5	↑	32.5~58.3	u/ml
Haptoglobin	93.30		110.50		32~205	mg/dl
Blood glucose	5.6		6.1		3.9~6.1	mmol/l
Total cholesterol	6.12	↑	7.04	↑	2.80~5.20	mmol/l
Triacylglycerol	2.33	↑	1.81		0.34~2.26	mmol/l

Code	Pre-Injection	Twelve Months Post-Injection	Normal Range	Unit
Prothrombin time	13.3	12.4	11.0~14.5	sec
International normalized ratio	0.99	0.95	0.80~1.20	INR
Activated partial thromboplastin time	35.3	33.0	28~45	s
Thrombin time	18.7	19.7	14.0~21.0	s
Fibrinogen	2.98	2.74	2.00~4.00	g/l
D-Dimer	0.24	0.23	0.00~0.50	ug/ml
Prothrombin time ratio	102	110	70~150	%
Code	Pre-Injection	Twelve Months Post-Injection	Normal Range	Unit
Glycated hemoglobin	5.9	5.9	4.0~6.0	%

Table S8. Routine urine test. The routine urinalysis of patient 2 was unremarkable.

Code	Pre-Injection	Twelve Months Post-Injection	Normal Range	Unit
Urine glucose	-	-	-	
Ketone body	-	-	-	
Occult blood	-	-	-	
Protein	-	-	-	
Nitrite	-	-	-	
Bilirubin	-	-	-	
Specific gravity	>=1.030 ↑	1.025	1.003~1.030	
Urine PH value	5.5	6.0	5.0~6.5	
Urobilinogen	3.2	16	3.0~16.0	umol/l
Leukocyte	-	-	-	
White blood cell count	6	6	0~28	/ul
Red blood cell count	2	2	0~17	/ul
Squamous epithelial cells	2	1	0~28	/ul
Non-squamous epithelial cells	-	1	0~6	/ul
Trichomonas	-	-	0~1	/ul
Kidney epithelial cells	-	-	0~6	/ul
Transparent tube	-	-	0~2	/ul
Particle tube	-	-	0~1	/LPF
Cell tube	-	-	0~1	/LPF
Triphosphate crystal	-	-		
Calcium oxalate crystal	-	-		
Leucine crystal	-	-		
Cystine crystals	-	-		

Table S9. Transfusion-associated contagion tests. The contagion tests of patient 2 showed specific antibodies to the hepatitis B virus. The other three transfusion-associated contagion tests (hepatitis C, syphilis, AIDS) were negative.

Code	Pre-Injection	Twelve Months Post-Injection
Hepatitis B virus surface antigen	Negative	Negative
Hepatitis B virus surface antibody	Weak Positive	Weak Positive
Hepatitis B virus e antigen	Negative	Negative
Hepatitis B virus e antibody	Negative	Negative
Hepatitis B virus core antibody	Positive	Positive
Hepatitis B virus antibody-immunoglobulin M	Negative	Negative
Hepatitis B virus pre-S1 antigen	Negative	Negative
Hepatitis C virus antibody	Negative	Negative
Treponema pallidum particle agglutination test	Negative	Negative
Rapid plasma regain test	Negative	Negative
Human immunodeficiency virus antibody	Negative	Negative

Patient 3

HR: 69 bp QRS duration: 0.08s
P-R interval: 0.20s Q-T interval: 0.39s
QTc: 0.42 Axis: 54 °
V1R+V5S: 0.35mV V5R+V1S: 1.74mV




Fig. S14. The ECG examination. The pre-operative ECG of patient 3 was unremarkable.



Fig. S15. Chest X-ray film. The chest X-ray result of patient 3 was unremarkable.

Table S10. Blood tests. The blood tests of patient 3 indicated mild hyperlipidemia, which had no obvious influence on the implementation of the surgery.

Code	Pre-Injection	Six Months Post-Injection	Normal Range	Unit
White blood cell count	5.45	4.83	4.0~10.0	10 ⁹ /L
Red blood cell count	5.28	4.89	4.3~5.8	10 ¹² /L
Hemoglobin	159	152	130~175	g/l
Packed red blood cell volume	46.1	42.8	40~50	%
Red blood cell volume distribution width-coefficient of variation	11.9	12.4	10.0~15.0	%
Red blood cell volume distribution width-standard deviation	37.6	39.0	35.0~50.0	fL
Mean corpuscular volume	87.3	87.5	80.0~100.0	fL
Mean corpuscular hemoglobin	30.1	31.1	27.0~33.0	Pg
Mean corpuscular hemoglobin concentration	345	355	320~360	g/l
Platelet count	151	105	100~400	10 ⁹ /L
Platelet distribution width	10.8	12.2	9.0~17.00	
Thrombocytocrit	0.14 ↓	0.11 ↓	0.16~0.22	%
Mean platelet volume	9.5	10.7	9.0~16.0	fL
Platelet-larger cell ratio	21.5	30.8	14.0~46.0	%
Percentage of neutrophil	62.3	57.7	50.0~70.0	%
Percentage of lymphocyte	29.7	32.4	20.0~40.0	%
Percentage of eosinophil	1.7	2.3	0.5~5.0	%
Percentage of monocyte	5.9	7.3	3.0~8.0	%
Percentage of basophil	0.4	0.3	0.0~1.0	%
Neutrophil count	3.40	2.21	2.0~7.0	10 ⁹ /L
Lymphocyte count	1.62	1.24	0.8~4.0	10 ⁹ /L
Monocyte count	0.32	0.28	0.10~0.80	10 ⁹ /L
Eosinophil count	0.09	0.09	0.00~0.50	10 ⁹ /L
Basophil count	0.02	0.01	0.00~0.10	10 ⁹ /L
Code	Pre-Injection	Six Months Post-Injection	Normal Range	Unit
Alanine aminotransferase	29	53	0~65	u/l
Aspartate aminotransferase	18	26	15~37	u/l
Total protein	76	65	64~82	g/l
Albumin	49	40	35~54	g/l

Globulin	27		24		20~40	g/l
Albumin/globulin	1.8		1.66		1.2~2.5	
γ-Glutamyltransferase	37		49		15~85	u/l
Prealbumin	350		310		200~400	mg/l
Alkaline phosphatase	95		103		50~136	u/l
Blood urea nitrogen	6.6	↑	5.6		2.5~6.4	mmol/l
Creatinine	78		77		53~115	umol/l
Uric acid	0.32		0.37		0.202~0.417	mmol/l
Total bilirubin	16		16		0~17	umol/l
Connect bilirubin	7	↑	3		1~5	umol/l
Total bile acid	6		2		0.0~10.0	umol/l
High density lipoprotein	1.16		0.84	↓	0.910~2.060	mmol/l
Low density lipoprotein	2.79		2.24		0.00~3.36	mmol/l
Apoprotein A	1.29		1.00	↓	1.100~1.700	g/l
Apoprotein B	1.000		0.800		0.800~1.550	g/l
Apoprotein E	39		35		27~45	mg/l
Lipoprotein small a	38		42		0~75	nmol/l
Small dense low density lipoprotein	1.90	↑	1.87	↑	0.26~1.36	mmol/l
Calcium	2.32		2.32		2.04~2.74	mmol/l
Phosphorus	0.97		1.23		0.80~1.60	mmol/l
Potassium	4.3		4.4		3.5~5.4	mmol/l
Sodium	140		139		135~147	mmol/l
Chloride	102		105		96~108	mmol/l
Carbon dioxide binding capacity	26		23		21~32	mmol/l
Lactate dehydrogenase	149		175		81~234	u/l
Creatine kinase	75		98		39~308	u/l
Complement 3c	1.07		1.12		0.9~1.8	g/l
Complement 4	0.31		0.29		0.1~0.4	g/l
Complement 1q	195.5		210.4		159~233	mg/l
Total complement	82.5	↑	84.7	↑	32.5~58.3	u/ml
Haptoglobin	86.50		98.20		32~205	mg/dl
Blood glucose	5.7		4.7		3.9~6.1	mmol/l
Total cholesterol	4.36		3.68		2.80~5.20	mmol/l
Triacylglycerol	1.23		2.24		0.34~2.26	mmol/l

Code	Pre-Injection	Six Months Post-Injection	Normal Range	Unit
Prothrombin time	13.3	11.1	11.0~14.5	sec
International normalized ratio	1.00	0.94	0.80~1.20	INR
Activated partial thromboplastin time	37.7	32.8	28~45	s
Thrombin time	18.0	16.8	14.0~21.0	s
Fibrinogen	3.43	2.72	2.00~4.00	g/l
D-Dimer	0.28	0.31	0.00~0.50	ug/ml
Prothrombin time ratio	99	97	70~150	%
Code	Pre-Injection	Six Months Post-Injection	Normal Range	Unit
Glycated hemoglobin	5.3	4.89	4.0~6.0	%

Table S11. Routine urine test. The routine urinalysis of patient 3 was unremarkable.

Code	Pre-Injection Results	Normal Range	Unit
Urine glucose	-	-	
Ketone body	-	-	
Occult blood	-	-	
Protein	-	-	
Nitrite	-	-	
Bilirubin	-	-	
Specific gravity	>=1.030 ↑	1.003~1.030	
Urine PH value	7.0 ↑	5.0~6.5	
Urobilinogen	3.2	3.0~16.0	umol/l
Leukocyte	-	-	
White blood cell count	1	0~28	/ul
Red blood cell count	1	0~17	/ul
Squamous epithelial cells	-	0~28	/ul
Non-squamous epithelial cells	-	0~6	/ul
Trichomonas	-	0~1	/ul
Kidney epithelial cells	-	0~6	/ul
Transparent tube	-	0~2	/ul
Particle tube	-	0~1	/LPF
Cell tube	-	0~1	/LPF
Triphosphate crystal	-		
Calcium oxalate crystal	-		
Leucine crystal	-		
Cystine crystals	-		

Table S12. Transfusion-associated contagion tests. The contagion tests of patient 3 showed specific antibodies to the hepatitis B virus. The other three transfusion-associated contagion tests (hepatitis C, syphilis, AIDS) were negative.

Code	Pre-Injection Results
Hepatitis B virus surface antigen	Negative
Hepatitis B virus surface antibody	Positive
Hepatitis B virus e antigen	Negative
Hepatitis B virus e antibody	Positive
Hepatitis B virus core antibody	Positive
Hepatitis B virus antibody-immunoglobulin M	Negative
Hepatitis B virus pre-S1 antigen	Negative
Hepatitis C virus antibody	Negative
Treponema pallidum particle agglutination test	Negative
Rapid plasma regain test	Negative
Human immunodeficiency virus antibody	Negative




Fig. S16. ELISA results detect antibodies against SpCas9. Tetanus toxoid and human albumin in the sera from different donors served as a positive and negative control, respectively. The Cas9-specific antibodies were determined at different time points. The change in Cas9 antibody levels before and after HELP administration was insignificant. All samples above the dotted line were considered antibody-positive. The dotted line represents the mean absorbance of the negative control, human albumin, plus three s.d. from the mean. Data and error bars represent mean \pm s.e.m.; n.s., non-significant; unpaired two-tailed Student's t-tests.




Fig. S17. In vitro antiviral activity of the clinical grade HELP. 4×10^4 293T cells were seeded in a 48-well plate and transduced with 400 ng of HELP or scramble control on the following day. The medium was refreshed 12 h post-infection (h.p.i.). 24 h after transduction, cells were infected with HSV-1-GFP at an MOI of 1. The cells and supernatants were harvested at 24 and 48 h.p.i. for flow cytometry (A) and plaque assay (B), respectively. 293T cells were transduced with HELP for 24 h and then infected with HSV-1-GFP. $n=3$ biologically independent samples. Data and error bars represent mean \pm s.e.m.; n.s., non-significant; *** $P<0.001$; unpaired two-tailed Student's t-tests.




Fig. S18. Gating strategies used for cell sorting analysis. Gate strategy to sort GFP positive cells from HSV1-GFP infected 293T cells on supplementary figure S17a.

5




Fig. S19. Validity of patient samples. GAPDH gene in the tear swab of patients was tested by PCR to verify the validity of patient samples. Eye swab samples of 1 day pre-injection, 1 month, 6 months, 12 months post-injection of patient 1 & 2, and samples of 1 day pre-injection, 1 month, 3 months, 6 months post-injection of patient 3 were used as templates for PCR followed by nucleic acid gel electrophoresis. The results showed that GAPDH was positive in all samples, indicating that the swabs were valid.




Fig. S20. Gene editing efficiency of the clinical grade HELP. TIDE analysis of indels in the HSV-1 genome. 2×10^4 293T cells were incubated with 200 ng P24 HELP, then infected with HSV-1 with MOI=1. Virus DNA was collected at 2 days post-infection for Sanger sequencing. n=3 biologically independent samples.

5

Table S13. The primers for UL8 and UL29 amplification.

Target sites	gRNA Sequence (5'-3')	Primer names	Sequence (5'-3')
UL8	GGGGCAGCCATACCGCGTAA	Y1-F	gagccgtagaatcccgcag
		Y2-R	aaacctaccaaacagacaa
UL29	GCGAGCGTACACGTATCCC	Y3-F	gggtgtagtccgaaaagccaa
		Y4-R	cacgccccaggtaaagtgta

Table 14. The quality report of HELP.

Source	OBiO Technology (Shanghai) Corp., Ltd.	Specification	0.25 ml/vial
Test Category	Test	Result	
Quantification	p24 protein content	1.19E+04 ng p24/ml	
Safety	Bacteria	Negative	
	Mycoplasma	Negative	
Conclusion	Qualified		

Table S15. The list of protocol changes.

Section of Current protocol	Rationale	Current Version
Outcomes Measures	Adjust the contents and priorities of outcomes	Primary outcome: HSV-1 testing outcome of the intervention eye; adverse effects. Secondary outcome: patient graft survival; best-corrected visual acuity.
2.1	Adjust the inclusion criteria	Patients with refractory keratitis caused by herpes virus type I who has acute corneal perforation or had at least one time failed corneal transplant due to the virus relapse.